ENDRA Life Sciences Inc. (NDRA) key numbers that make it a Strong Buy For Now

ENDRA Life Sciences Inc. (NASDAQ: NDRA) is -44.79% lower on its value in year-to-date trading and has touched a low of $0.60 and a high of $2.25 in the current 52-week trading range. The NDRA stock was last observed hovering at around $0.93 in the last trading session, with the day’s loss setting it 0.0% off its average median price target of $4.38 for the next 12 months. It is also 84.5% off the consensus price target high of $6.00 offered by 2 analysts, but current levels are 66.18% higher than the price target low of $2.75 for the same period.

Currently trading at $0.93, the stock is 19.10% and 20.22% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.59 million and changing -0.27% at the moment leaves the stock -19.36% off its SMA200. NDRA registered -14.12% loss for a year compared to 6-month loss of -8.17%. The firm has a 50-day simple moving average (SMA 50) of $0.7830 and a 200-day simple moving average (SMA200) of $1.0761.

The stock witnessed a 36.40% gain in the last 1 month and extending the period to 3 months gives it a -16.44%, and is 0.82% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.18% over the week and 11.82% over the month.

ENDRA Life Sciences Inc. (NDRA) has around 15 employees, a market worth around $13.50M and $0.00M in sales. Distance from 52-week low is 54.84% and -58.78% from its 52-week high.

ENDRA Life Sciences Inc. (NDRA) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for ENDRA Life Sciences Inc. (NDRA) is a “Buy”. 2 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 2 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

ENDRA Life Sciences Inc. is expected to release its quarterly report on 08/05/2020 and quarterly earnings per share for the current quarter are estimated at -$0.27.The EPS is expected to shrink by -7.50% this year.

ENDRA Life Sciences Inc. (NDRA) Top Institutional Holders

14 institutions hold shares in ENDRA Life Sciences Inc. (NDRA), with 500.7k shares held by insiders accounting for 3.45% while institutional investors hold 9.19% of the company’s shares. The shares outstanding are 11.51M, and float is at 13.92M with Short Float at 4.46%. Institutions hold 8.87% of the Float.

The top institutional shareholder in the company is ICM Asset Management, Inc. with over 0.88 million shares valued at $0.63 million. The investor’s holdings represent 6.04% of the NDRA Shares outstanding. As of Mar 30, 2020, the second largest holder is Vanguard Group, Inc. (The) with 97900.0 shares valued at $70703.0 to account for 0.67% of the shares outstanding. The other top investors are Geode Capital Management, LLC which holds 63928.0 shares representing 0.44% and valued at over $46168.0, while Susquehanna International Group, LLP holds 0.36% of the shares totaling 52588.0 with a market value of $37979.0.

ENDRA Life Sciences Inc. (NDRA) Insider Activity

A total of 17 insider transactions have happened at ENDRA Life Sciences Inc. (NDRA) in the last six months, with sales accounting for 0 and purchases happening 17 times.